Investing.com - Financial Markets Worldwide

Mithra Pharmaceuticals Sa (MITRA)

Symbol
Exchange
Currency
MITRA
BrusselsEURReal-time
1TM
FrankfurtEURDelayed
3.00
-0.09(-2.91%)
-Closed.
Currency in EUR
  • Volume:
    140,231
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2.94 - 3.10

MITRA Overview

Prev. Close
3.09
Day's Range
2.94-3.1
Revenue
67M
Open
3.1
52 wk Range
2.28-13.5
EPS
-2.1
Volume
140,231
Market Cap
169.77M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
302,133
P/E Ratio
-1.45
Beta
0.66
1-Year Change
-78.57%
Shares Outstanding
56,591,094
Next Earnings Date
-
What is your sentiment on Mithra Pharmaceuticals Sa?
or
Market is currently closed. Voting is open during market hours.

Mithra Pharmaceuticals Sa News

Mithra Pharmaceuticals Sa Company Profile

Mithra Pharmaceuticals Sa Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
300
Market
Belgium
  • Type:Equity
  • Market:Belgium
  • ISIN:BE0974283153

Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The Company also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The Company operates in more than 100 countries around the world and is headquartered in Liege, Belgium.

Read More

Income Statement

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellBuyStrong SellSellStrong Sell
SummaryStrong SellNeutralStrong SellStrong SellStrong Sell

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Tesla
190.41192.36187.15-1.81-0.94%115.62MNASDAQ
Apple
160.25160.34157.85+1.32+0.83%56.97MNASDAQ
Coca-Cola
60.9061.0159.91+0.98+1.64%12.65MNYSE
Meta Platforms
206.01207.58203.55+1.73+0.85%27.63MNASDAQ
Alphabet A
105.44105.49103.84-0.16-0.15%30.02MNASDAQ
Microsoft
280.57280.63275.28+2.91+1.05%28.01MNASDAQ
Pfizer
40.3940.4639.87+0.21+0.52%17.13MNYSE
AMD
97.9599.5296.74-2.33-2.32%64.14MNASDAQ
Amazon.com
98.1398.3096.40-0.58-0.59%55.74MNASDAQ
Marriott Int
156.56158.27153.56-3.42-2.14%2.51MNASDAQ
NVIDIA
267.79271.67263.55-4.12-1.52%45.08MNASDAQ
Palantir
8.208.358.06-0.13-1.56%17.87MNYSE
Alphabet C
106.07106.16104.74-0.18-0.17%25.05MNASDAQ
Shopify Inc
44.9845.5844.24-0.81-1.77%11.13MNYSE
Constellation Acquisition
10.3310.3310.33+0.050+0.49%193.00NYSE
  • Mega deal to come with catalent (CTLT) ?
    0
    • The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
      0
      • Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
        0
        • NEXSTELLIS® oral contraceptive now available in Australia26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia. NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent. Leon Van Rompay, CEO Mithra Women’s Health
          0
          • LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 54 million available to Mithra.
            0
            • 1 month later and 8.16, where's the bottom?
              0
              • 11.70, curious how low this can go. price now certainly does not represent future profits
                0
                • 14.00? Time to accumulate for a near future
                  0
                  • Approval in EU is a fact. next US!
                    0
                    • Approval US is also a fact !
                      0
                  • Approval for Canada is now a fact!
                    0